Refractory Acute Myeloid Leukemia – Pipeline Review, H2 2016
- Pages: 477
- Published: November 2016
- Report Code: GMDHC8705IDB
Global Markets Direct’s, ‘Refractory Acute Myeloid Leukemia – Pipeline Review, H2 2016’, provides an overview of the Refractory Acute Myeloid Leukemia pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Refractory Acute Myeloid Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Refractory Acute Myeloid Leukemia and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape of Refractory Acute Myeloid Leukemia
The report reviews pipeline therapeutics for Refractory Acute Myeloid Leukemia by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved Refractory Acute Myeloid Leukemia therapeutics and enlists all their major and minor projects
The report assesses Refractory Acute Myeloid Leukemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news related to pipeline therapeutics for Refractory Acute Myeloid Leukemia
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategiesIdentify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand important and diverse types of therapeutics under development for Refractory Acute Myeloid Leukemia
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Refractory Acute Myeloid Leukemia pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies mentioned
4SC AG
AbbVie Inc
Actinium Pharmaceuticals Inc
ADC Therapeutics Sarl
Aeglea BioTherapeutics Inc
Agios Pharmaceuticals Inc
Aileron Therapeutics Inc
Amgen Inc
Arog Pharmaceuticals Inc
Array BioPharma Inc
Astellas Pharma Inc
AstraZeneca Plc
AVEO Pharmaceuticals Inc
Bellicum Pharmaceuticals Inc
Bio-Cancer Treatment International Ltd
BioLineRx Ltd
BioSight Ltd
Boehringer Ingelheim GmbH
Boston Biomedical Inc
Bristol-Myers Squibb Company
Calithera Biosciences Inc
Celgene Corp
Cornerstone Pharmaceuticals Inc
CSPC Pharmaceutical Group Limited
CTI BioPharma Corp
Daiichi Sankyo Company Ltd
Eisai Co Ltd
Eli Lilly and Company
EpiZyme Inc
Exelixis Inc
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
FLX Bio, Inc.
FORMA Therapeutics Inc
Fujifilm Corp
GlaxoSmithKline Plc
GlycoMimetics Inc
Igenica Biotherapeutics Inc
Incyte Corp
Io Therapeutics Inc
JW Pharmaceutical Corp
Karyopharm Therapeutics Inc
Kyowa Hakko Kirin Co Ltd
MacroGenics Inc
Merck & Co Inc
Merck KGaA
Millennium Pharmaceuticals Inc
NantKwest Inc
Novartis AG
Oxford BioTherapeutics Ltd
Pfizer Inc
Pharma Mar SA
Polaris Pharmaceuticals Inc
Seattle Genetics Inc
Sunesis Pharmaceuticals Inc
TaiGen Biotechnology Co Ltd
Tolero Pharmaceuticals Inc
Tragara Pharmaceuticals Inc
VioQuest Pharmaceuticals Inc
ZIOPHARM Oncology Inc
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.